132 related articles for article (PubMed ID: 10070170)
1. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy.
Remuzzi A; Perico N; Sangalli F; Vendramin G; Moriggi M; Ruggenenti P; Remuzzi G
Am J Physiol; 1999 Mar; 276(3):F457-66. PubMed ID: 10070170
[TBL] [Abstract][Full Text] [Related]
2. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.
Perico N; Remuzzi A; Sangalli F; Azzollini N; Mister M; Ruggenenti P; Remuzzi G
J Am Soc Nephrol; 1998 Dec; 9(12):2308-17. PubMed ID: 9848785
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy.
Remuzzi A; Perticucci E; Ruggenenti P; Mosconi L; Limonta M; Remuzzi G
Kidney Int; 1991 Jun; 39(6):1267-73. PubMed ID: 1716713
[TBL] [Abstract][Full Text] [Related]
4. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
Pechère-Bertschi A; Nussberger J; Decosterd L; Armagnac C; Sissmann J; Bouroudian M; Brunner HR; Burnier M
J Hypertens; 1998 Mar; 16(3):385-93. PubMed ID: 9557932
[TBL] [Abstract][Full Text] [Related]
5. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators.
Larochelle P; Flack JM; Marbury TC; Sareli P; Krieger EM; Reeves RA
Am J Cardiol; 1997 Dec; 80(12):1613-5. PubMed ID: 9416950
[TBL] [Abstract][Full Text] [Related]
6. Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade.
Ruggenenti P; Mosconi L; Sangalli F; Casiraghi F; Gambara V; Remuzzi G; Remuzzi A
Kidney Int; 1999 Mar; 55(3):984-94. PubMed ID: 10027935
[TBL] [Abstract][Full Text] [Related]
7. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.
Russo D; Minutolo R; Pisani A; Esposito R; Signoriello G; Andreucci M; Balletta MM
Am J Kidney Dis; 2001 Jul; 38(1):18-25. PubMed ID: 11431176
[TBL] [Abstract][Full Text] [Related]
8. Influence of irbesartan and enalapril on changes of renal function associated with the established phase of l-NAME hypertension.
Jover B; Herizi A; Casellas D; Mimran A
J Hypertens; 2001 Nov; 19(11):2039-46. PubMed ID: 11677370
[TBL] [Abstract][Full Text] [Related]
9. Effects of angiotensin II receptor blockade on remnant glomerular permselectivity.
Mayer G; Lafayette RA; Oliver J; Deen WM; Myers BD; Meyer TW
Kidney Int; 1993 Feb; 43(2):346-53. PubMed ID: 7680077
[TBL] [Abstract][Full Text] [Related]
10. Enalapril, irbesartan, and angiotensin-(1-7) prevent atrial tachycardia-induced ionic remodeling.
Liu E; Xu Z; Li J; Yang S; Yang W; Li G
Int J Cardiol; 2011 Feb; 146(3):364-70. PubMed ID: 19732978
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-converting enzyme inhibition ameliorates the defect in glomerular size selectivity in hyponatremic hypertensive syndrome.
Remuzzi A; Schieppati A; Battaglia C; Remuzzi G
Am J Kidney Dis; 1989 Sep; 14(3):170-7. PubMed ID: 2476029
[TBL] [Abstract][Full Text] [Related]
12. ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome.
Ruggenenti P; Mosconi L; Vendramin G; Moriggi M; Remuzzi A; Sangalli F; Remuzzi G
Am J Kidney Dis; 2000 Mar; 35(3):381-91. PubMed ID: 10692263
[TBL] [Abstract][Full Text] [Related]
13. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy.
Nakamura T; Ushiyama C; Suzuki S; Hara M; Shimada N; Sekizuka K; Ebihara I; Koide H
Am J Nephrol; 2000; 20(5):373-9. PubMed ID: 11092994
[TBL] [Abstract][Full Text] [Related]
14. Acute renal effects of AT1-receptor blockade after exogenous angiotensin II infusion in healthy subjects.
Schmitt F; Martinez F; Brillet G; Nguyen-Khoa T; Brouard R; Sissmann J; Lacour B; Grunfeld JP
J Cardiovasc Pharmacol; 1998 Feb; 31(2):314-21. PubMed ID: 9475275
[TBL] [Abstract][Full Text] [Related]
15. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade.
Ferrari P; Marti HP; Pfister M; Frey FJ
J Hypertens; 2002 Jan; 20(1):125-30. PubMed ID: 11791035
[TBL] [Abstract][Full Text] [Related]
16. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension.
Chiou KR; Chen CH; Ding PY; Chen YT; Ting CT; Huang JL; Chiang AH; Liu CP; Tseng CJ; Chao CT; Chang MS
Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):368-76. PubMed ID: 10862446
[TBL] [Abstract][Full Text] [Related]
18. ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study.
Pozzi C; Del Vecchio L; Casartelli D; Pozzoni P; Andrulli S; Amore A; Peruzzi L; Coppo R; Locatelli F; ;
J Nephrol; 2006; 19(4):508-14. PubMed ID: 17048209
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat.
Remuzzi A; Puntorieri S; Battaglia C; Bertani T; Remuzzi G
J Clin Invest; 1990 Feb; 85(2):541-9. PubMed ID: 1688888
[TBL] [Abstract][Full Text] [Related]
20. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
